Nivolumab for EBV-related lymphomas and abnormal immune illnesses
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy, Infections clinical trials.
This trial tests nivolumab (an immune therapy) for people with EBV-positive lymphoma or EBV-driven immune/lymph conditions. It may help shrink tumors or control the disease when standard treatments have not worked or are not suitable.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have lab-confirmed EBV-positive lymphoma or EBV-positive abnormal lymph/immune disease (a pathology or cytology test result).
- Your diagnosis must be one of the listed types (such as lymphomatoid granulomatosis, chronic active EBV disease, EBV-positive DLBCL, or certain EBV-related post-transplant conditions—solid organ transplant after is excluded).
- You must be at least 12 years old, and if you’re 12–17 you must meet the study weight and dosing safety rules (including discussing dosing safety if under 40 kg).
- You need to be able to recover from treatment: there must be enough time since prior anti-cancer therapy (at least 2 weeks) and enough time since stem cell transplant/DLI (at least 100 days).
- Your blood counts and organ/liver/kidney tests must meet the study thresholds, and you must have measurable or evaluable disease.
- You must be willing to provide tumor tissue for study tests (archival tissue is required; if not enough, a new pre-treatment biopsy may be needed).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests a lab-made immune cell treatment (cytotoxic T-lymphocytes) for certain lymphomas and related diseases that test positive for the Epstein-Barr virus (EBV). It may help your immune system attack EBV-infected cancer cells, especially after the cancer has come back or when transplant isn’t suitable.
This trial studies pomalidomide plus nivolumab in people with cancers linked to certain viruses (or hepatitis B/C). It may help the immune system fight the cancer when the disease has returned, progressed, or can’t be fully treated with standard options.
This Phase 1 study tests an immune-cell therapy made to recognize EBV (a common virus) in people whose lymphoma contains EBV. It may help control EBV-driven cancers, especially when standard treatment isn’t working or can’t be used.
This trial tests a new immune therapy for people with Epstein-Barr virus (EBV)-related lymphoproliferative diseases, including chronic active EBV and conditions that can occur after an organ or stem cell transplant. It aims to see if the therapy can safely control the disease.
This trial tests an experimental mRNA vaccine designed to target cancer cells infected with the Epstein-Barr virus (EBV). It is for people with certain types of lymphoma that have come back or not responded to standard treatments. The goal is to see if the vaccine can help the immune system fight the cancer.
This trial tests a combination of four drugs for patients with a type of lymphoma that is linked to the Epstein-Barr virus and has come back or not responded to previous treatment. The goal is to see if this combination can help control the disease.
Hear when a new Epstein-Barr Virus Infections trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.